VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 78 filers reported holding VAXCYTE INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,342,011 | +19.6% | 712,868 | +17.2% | 0.01% | +11.1% |
| Q2 2023 | $30,386,992 | +66.3% | 608,470 | +24.8% | 0.01% | +50.0% |
| Q1 2023 | $18,276,485 | -22.0% | 487,633 | -0.2% | 0.01% | -25.0% |
| Q4 2022 | $23,422,568 | +182.7% | 488,479 | +41.5% | 0.01% | +166.7% |
| Q3 2022 | $8,286,000 | +31.5% | 345,226 | +19.2% | 0.00% | +50.0% |
| Q2 2022 | $6,303,000 | -0.5% | 289,647 | +10.4% | 0.00% | 0.0% |
| Q1 2022 | $6,335,000 | +9.9% | 262,291 | +8.2% | 0.00% | 0.0% |
| Q4 2021 | $5,765,000 | -4.4% | 242,319 | +1.9% | 0.00% | 0.0% |
| Q3 2021 | $6,032,000 | +55.2% | 237,748 | +37.7% | 0.00% | +100.0% |
| Q2 2021 | $3,886,000 | +44.5% | 172,603 | +26.7% | 0.00% | 0.0% |
| Q1 2021 | $2,690,000 | -13.9% | 136,178 | +15.8% | 0.00% | 0.0% |
| Q4 2020 | $3,125,000 | -45.5% | 117,593 | +1.3% | 0.00% | -66.7% |
| Q3 2020 | $5,732,000 | – | 116,065 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |